Givastomig

YOL104－2 是一款经生物工程改造的三价多功能肽体，引入了核心干扰素模拟物，有望成为眼表鳞状肿瘤（OSSN）的同类首创疗法。 Visara 是新桥生物控股眼科子公司。 上海2026年10月20日 美通社 －－ 新桥生物（纳斯达克股票代码：NBP，下称“新桥生物”或“公司”）控股眼科子公司 Visara, Inc.（以下简称“Visara”）今日宣布，已与生物科技公司YOLO Immune（下称“YOLO”）签署资产购买选择权协议。该选择权协议赋予 Visara 独家选择权，可收购 YOL104 项目的全球权益，开发与商业化 YOL104－2，用于治疗眼表鳞状肿瘤（OSSN）。YOL104－2 是一款三价干扰素α（IFN－α）肽体，目前正在开展用于治疗 OSSN 的研究。 Visara 总裁兼首席执行官 Jeffrey Nau 博士表示：“YOL104－2 对于Visara的管线，是充满吸引力的潜在补充，与我们构建差异化眼科产品布局的战略高度契合。通过该协议，我们有机会将研发工作拓展到一个存在显著未满足需求的领域。在该领域，目前还没有一款疗法获得美国食品药品监督管理局（FDA）的批准。” 新桥生物首席执行官 Srishti Gupta 博士表示：“此次交易体现了新桥生物在管线布局上的审慎理念：精准识别具有差异化优势的创新项目，结合公司聚焦专业领域的运营能力，为每项资产打造最匹配的模式，以推进项目开发。通过获得YOL104－2的独家选择权，Visara不仅有机会更进一步评估这一针对眼表疾病的差异化项目，也能在资产配置与管线布局上保持灵活性。” 根据该选择权协议条款，Visara 将支付一笔首付款，以换取收购 YOL104 项目全球所有权与权益的独家选择权。若 Visara 行使选择权并完成收购，YOLO 将获得行权付款，并有资格获得开发、监管、商业化里程碑付款，以及基于净销售额的分级特许权使用费。其他财务条款未予披露。 关于 YOL104－2 YOL104－2 是一款经生物工程改造的三价多功能肽体，引入了核心干扰素模拟物，用于治疗眼表鳞状肿瘤。 关于眼表鳞状肿瘤（OSSN） 眼表鳞状肿瘤是角膜和结膜表面的一系列癌性和癌前病变的统称，与阳光暴露、HPV 感染及免疫系统减弱相关，是眼表最常见的非色素性肿瘤。 关于 Visara Visara是一家临床阶段生物技术公司，致力于开发用于治疗影响眼前节与眼后节的眼科疾病的新一代生物疗法。视力对健康至关重要，而眼科领域存在着巨大的未满足需求。从角膜到视网膜，Visara的管线已覆盖眼前节与眼后节疾病。 Visara是新桥生物（纳斯达克代码：NBP）控股的眼科子公司，产品管线包括用于新生血管性视网膜疾病的在研四价VEGF－A × ANG－2肽体VIS－101，以及用于神经营养性角膜炎的新一代在研重组人神经生长因子疗法 VIS－102。 关于 新桥生物 新桥生物（纳斯达克股票代码：NBP）是一家全球性生物技术公司，专注于推进肿瘤和眼科领域的治疗。公司致力于发现具备差异化优势的治疗机会，通过临床研究验证其价值，并针对各项目特点，采用最合适的开发、融资与合作策略。 新桥生物的核心管线以Givastomig和子公司Visara旗下管线为代表。Givastomig是一款 Claudin 18.2 × 4－1BB 双特异性抗体，正开发用于胃肠道恶性肿瘤的潜在治疗；Visara是公司控股的眼科子公司。通过Visara，新桥生物正在打造多元化的眼科管线布局，旨在满足覆盖眼前节与眼后节疾病的未满足需求。 公司的目标是持续发现差异化创新资源、高效推进开发，并选择最优路径将创新疗法带给患者，从而打造一家可持续发展的全球性生物技术公司。 欲了解更多信息，请访问www.novabridge.com，并关注新桥生物LinkedIn。 前瞻性声明 本公告包含前瞻性声明。这些声明依据1995年美国《私人证券诉讼改革法案》的“安全港”条款作出。可以通过术语例如“将”“预计”“相信”“旨在”“预期”“未来”“打算”“计划”“潜在”“估计”“有信心”“期待”等以及类似表述（或其反义表述）来识别这些前瞻性声明。新桥生物与Visara也可能在其提交给美国证券交易委员会（SEC）的定期报告、向股东发布的年度报告、新闻稿及其他书面材料中，以及公司高管、董事或员工向第三方所作的口头陈述中作出书面或口头的前瞻性声明。凡不属于历史事实的陈述（包括关于公司的信念和预期的陈述）均为前瞻性声明。本新闻稿中的前瞻性声明包括但不限于以下内容：潜在行使收购选择权并开发YOL104－2；根据该选择权协议潜在实现的开发、监管和商业化里程碑；根据该选择权协议预计支付的里程碑款项和特许权使用费；Visara候选药物（包括 VIS－101和VIS－102）的潜在获益；Visara候选药物（包括 VIS－101和VIS－102）的战略、临床开发、计划、时间安排、结果、安全性和有效性。 前瞻性声明涉及的风险和不确定性可能导致实际结果与这些前瞻性声明中包含的结果存在重大差异，包括但不限于以下因素：新桥生物或Visara证明其候选药物安全性和有效性的能力；候选药物的临床结果（可能支持也可能不支持进一步开发、新药申请生物制品许可申请（NDABLA）的批准，或符合加速批准路径资格或获得加速批准）；相关监管机构（包括FDA）就新桥生物或Visara的候选药物监管审批所作决定的内容和时间；新桥生物或Visara在候选药物获批后的商业成功能力；新桥生物或Visara获得并维护其技术和药物知识产权保护的能力；新桥生物或Visara依赖第三方进行药物开发、生产制造及其他服务；新桥生物或Visara有限的运营历史，以及公司获得额外运营资金并完成其候选药物开发和商业化的能力；宏观经济状况的影响，包括通胀、关税、利率波动、监管不确定性、潜在的政府停摆、资本市场波动，以及包括世界不同地区持续武装冲突在内的区域性及其他全球事件；以及公司已于2026年4月7日向美国SEC提交并于2026年6月16日修订的20－F年度报告中“风险因素”部分更全面讨论的风险，以及公司随后向SEC提交的文件中讨论的潜在风险、不确定性和其他重要因素。所有前瞻性声明均基于公司当前可获得的信息。除法律要求外，公司不承担因获得新信息、未来事件或其他原因而公开更新或修订任何前瞻性声明的义务。

YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN) Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. (“Visara”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ: NBP), today announced that it has entered into an asset purchase option agreement (the “Option Agreement”) with YOLO Immune (“YOLO”). The Option Agreement provides Visara with an exclusive option to acquire worldwide rights to the YOL104 Program and develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN). YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody currently under investigation for the treatment of OSSN. “YOL104-2 represents an attractive potential addition to Visara’s pipeline and aligns well with our strategy to build a differentiated ophthalmology portfolio,” said Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Visara. “Through this agreement, we have secured the opportunity to potentially expand our development efforts into an additional area of significant unmet need where there is currently no FDA approved therapy.” “This transaction demonstrates the NovaBridge approach to disciplined portfolio building: identifying differentiated innovation, pairing it with focused operating expertise and advancing opportunities through the structure best suited to each asset,” said Srishti Gupta, M.D., M.P.P., Chief Executive Officer of NovaBridge. “By securing an exclusive option to acquire YOL104-2, Visara gains the opportunity to further evaluate a differentiated program in ocular surface disease while maintaining flexibility in capital allocation and portfolio development.” Under the terms of the Option Agreement, Visara will make an upfront payment in exchange for an exclusive option to acquire worldwide title and ownership of the YOL104 Program. If Visara exercises the option and completes the acquisition, YOLO would receive an exercise payment and would be eligible for development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. Additional financial terms were not disclosed. About YOL104-2 YOL-104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic for the treatment of ocular surface squamous neoplasia (OSSN). About Ocular Surface Squamous Neoplasia (OSSN) Ocular Surface Squamous Neoplasia (OSSN) is diagnosis that includes a wide range of cancerous and precancerous growths on the surface of the cornea and conjunctiva. It is linked to sun exposure, HPV infection and a weakened immune system, and it is the most common non-pigmented tumor of the ocular surface. About Visara Visara is a clinical stage biotechnology company dedicated to developing next-generation biologic therapies for ophthalmic diseases affecting both the front and back of the eye. From the cornea to the retina, Visara pursues the full spectrum of ocular disease as vision is irreplaceable, and the unmet need is profound. Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP). Its pipeline includes VIS-101, a tetravalent VEGF-A × ANG-2 peptibody being developed for neovascular retinal diseases, and VIS-102, a next-generation modified recombinant human nerve growth factor therapy being developed for neurotrophic keratitis. About NovaBridge Biosciences NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye. NovaBridge's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity. For more information, please visit and follow us on LinkedIn . Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “believes,” “designed to,” “anticipates,” “future,” “intends,” “plans,” “potential,” “estimates,” “confident,” and similar terms or the negative thereof. NovaBridge and Visara may also make written or oral forward-looking statements in NovaBridge’s periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NovaBridge’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential exercise of the option to acquire and development of YOL104-2; the potential achievement of development, regulatory and commercial milestones under the Option Agreement; expected milestone and royalty payments under the Option Agreement; the potential benefits of Visara’s product candidates, including VIS-101 and VIS-102; and the strategy, clinical development, plans, timing, results, safety and efficacy of Visara’s drug candidates, including VIS-101 and VIS-102. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: NovaBridge’s or Visara’s ability to demonstrate the safety and efficacy of their drug candidates; the clinical results for their drug candidates, which may or may not support further development or New Drug Application/Biologics License Application approval or eligibility for accelerated approval pathway or receipt of accelerated approval; the content and timing of decisions made by the relevant regulatory authorities, including the FDA, regarding regulatory approval of NovaBridge’s or Visara’s drug candidates; NovaBridge’s or Visara’s ability to achieve commercial success for their drug candidates, if approved; NovaBridge’s or Visara’s ability to obtain and maintain protection of intellectual property for their technology and drugs; NovaBridge’s or Visara’s reliance on third parties to conduct drug development, manufacturing and other services; NovaBridge’s or Visara’s limited operating history and their ability to obtain additional funding for operations and to complete the development and commercialization of their drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and those risks more fully discussed in the “Risk Factors” section in NovaBridge’s annual report on Form 20-F filed with the SEC on April 7, 2026, and amended on June 16, 2026, as well as the discussions of potential risks, uncertainties, and other important factors in NovaBridge’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to NovaBridge. NovaBridge undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. NovaBridge Investor & Media Contacts Investors: Bill Begien, SVP, Investor Relations +1-240-745-6330 bill.begien@novabridge.com IR@novabridge.com Media Inquiries: Eric Van Zanten, VP, Communications +1-610-529-6219 eric.vanzanten@novabridge.com